Adjuvant Trastuzumab Emtansine Improves Overall Survival in HER2+ Breast Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 16, 2025 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall survival more than trastuzumab alone, according to a study published in the Jan. 16 issue of the New England Journal of Medicine.
Charles E. Geyer Jr., M.D., from the National Surgical Adjuvant Breast and Bowel Project Foundation in Pittsburgh, and colleagues randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive 14 cycles of T-DM1 or trastuzumab (743 individuals in each treatment group).
With a median follow-up of 8.4 years, the researchers found that T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab (unstratified hazard ratio for invasive disease or death, 0.54; 95 percent confidence interval, 0.44 to 0.66). Seven-year invasive disease-free survival was 80.8 and 67.1 percent with T-DM1 and trastuzumab, respectively. A significantly lower risk for death was seen with T-DM1 versus trastuzumab (unstratified hazard ratio, 0.66; 95 percent confidence interval, 0.51 to 0.87; P = 0.003). Seven-year overall survival was 89.1 and 84.4 percent, respectively, with T-DM1 and trastuzumab. In 26.1 and 15.7 percent of patients in the T-DM1 and trastuzumab groups, respectively, adverse events of grade 3 or higher were noted.
"This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues," the authors write.
The study was funded by F. Hoffmann-La Roche/Genentech, the manufacturer of trastuzumab emtansine.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
WEDNESDAY, June 25, 2025 -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large...
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
FRIDAY, June 20, 2025 -- Nearly 40 percent of women with stage I breast cancer and two-thirds with stage II decide to extend endocrine therapy, according to a study published...
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.